Memantina Atb (Memantine Hydrochloride)

• Memantina Atb belongs to the NMDA receptor antagonist class and is used in the management of neurodegenerative dementia.
• Alzheimer’s disease (moderate to severe): helps improve cognition, functional abilities and overall clinical status in patients with moderate to severe Alzheimer’s disease.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor ion channel. By binding to the receptor with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury and supporting neuronal survival in the brain.

Memantina Atb may be associated with a range of adverse reactions.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Confusion: transient disorientation or difficulty concentrating.
• Fatigue: feeling unusually tired or lacking energy.
• Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

• Seizures: occurrence of convulsive episodes.
• Severe allergic reactions: rash, swelling, or difficulty breathing.
• Cardiac arrhythmia: irregular heart rhythm.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Psychosis: new or worsening hallucinations or delusional thoughts.

• Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.
• Renal function: adjust dose in patients with impaired clearance.
• Seizure history: monitor closely for new seizure activity.
• Cardiovascular disease: assess blood pressure and heart rhythm regularly.
• Hepatic impairment: use with caution in liver disease.
• Concomitant medications: review for drugs that may increase neurotoxicity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Atb can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism may increase neurotoxic risk.
• Other NMDA antagonists (e.g., ketamine): additive central nervous system effects.
• High‑dose quinidine: may raise memantine plasma levels.
• Strong renal inhibitors (e.g., cimetidine): can elevate memantine exposure.
• Anticholinergic agents: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely)

• NSAIDs: potential for increased blood pressure.
• Antihypertensives: monitor for additive hypotensive effect.
• SSRIs: watch for serotonin syndrome signs.
• Diuretics: assess electrolyte balance.
• Vitamin D supplements: observe calcium levels.